Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty.

Rahhal S, Clarke WL, Kletter GB, Lee PA, Neely EK, Reiter EO, Saenger P, Shulman D, Silverman L, Eugster EA

International journal of pediatric endocrinology26 Feb 2009Cited by 29 (Europe PMC)

PMID19956699PMCIDPMC2777002DOI10.1155/2009/812517PepBankPUB-19956699

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In children receiving histrelin, predicted adult height increased by 5.1 cm at 24 months (P = .0001).
In plain wordsIn children receiving histrelin, predicted adult height increased by 5.1 cm.
Peptide
Histrelin
Outcome
IncreasePredicted adult height
Study
n = 31
Outcome group
Linear growth · Musculoskeletal
Studied dose
Dose not stated · subcutaneous implantAs given in this study (human).
Measurements
Predicted adult height increase at 24 months
5.1 cm
children receiving a second implant
Source sentences
Summary
Predicted adult height increased by 5.1 cm at 24 months (P = .0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The study evaluates a second year of therapy in children with CPP who received a new implant after one year of treatment.
Summary · context
A prospective one-year study following an initial 12-month treatment period was conducted.
Report a problemFND-1995669903
02HumanNon-randomized trialSafety outcome
Minor implant site reactions occurred in 61% of children receiving a second histrelin implant.
In plain wordsMinor implant site reactions occurred in 61% of children receiving histrelin.
Peptide
Histrelin
Outcome
Not applicableMinor implant site reactions
Study
n = 31
Outcome group
Adverse events · Skin and wound
Studied dose
Dose not stated · subcutaneous implantAs given in this study (human).
Measurements
Subjects with minor implant site reactions
61%
subjects receiving a second implant
Source sentences
Summary
Minor implant site reactions occurred in 61%, while minor difficulties with explantation occurred in 32.2% of subjects.
2 context sentences(design, population, supporting numbers)
Summary · context
The study evaluates a second year of therapy in children with CPP who received a new implant after one year of treatment.
Summary · context
A prospective one-year study following an initial 12-month treatment period was conducted.
Report a problemFND-1995669904
03HumanNon-randomized trialSafety outcome
Minor explantation difficulties occurred in 32.2% of children receiving histrelin.
In plain wordsMinor removal difficulties occurred in 32.2% of children receiving histrelin.
Peptide
Histrelin
Outcome
Not applicableMinor explantation difficulties
Study
n = 31
Outcome group
Adverse events · Skin and wound
Studied dose
Dose not stated · subcutaneous implantAs given in this study (human).
Measurements
Subjects with minor difficulties with explantation
32.2%
subjects receiving a second implant
Source sentences
Summary
Minor implant site reactions occurred in 61%, while minor difficulties with explantation occurred in 32.2% of subjects.
2 context sentences(design, population, supporting numbers)
Summary · context
The study evaluates a second year of therapy in children with CPP who received a new implant after one year of treatment.
Summary · context
A prospective one-year study following an initial 12-month treatment period was conducted.
Report a problemFND-1995669905
04HumanNon-randomized trialEfficacy outcome
In treatment-naïve children receiving a second histrelin implant, peak LH declined from 0.92 to 0.51 mIU/mL between 12 and 24 months (P < .0001).
In plain wordsIn treatment-naïve children, peak LH decreased during the second year of histrelin treatment.
Peptide
Histrelin
Outcome
DecreasePeak LH in treatment-naïve subjects
Study
n = 18
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · subcutaneous implantAs given in this study (human).
Measurements
Peak LH at 12 months (mean, SD 0.58)
0.92 mIU/mL
naive subjects
Peak LH at 24 months (mean, SD 0.33)
0.51 mIU/mL
naive subjects
Source sentences
Summary
Peak LH declined from 0.92 +/- 0.58 mIU/mL at 12 months to 0.51 +/- 0.33 mIU/mL at 24 months (P < .0001) in naïve subjects,
2 context sentences(design, population, supporting numbers)
Summary · context
The study evaluates a second year of therapy in children with CPP who received a new implant after one year of treatment.
Summary · context
A prospective one-year study following an initial 12-month treatment period was conducted.
Report a problemFND-1995669901
05HumanNon-randomized trialEfficacy outcome
In previously treated children receiving histrelin, peak LH declined from 0.74 to 0.45 mIU/mL between 12 and 24 months (P = .0081).
In plain wordsIn previously treated children, peak LH decreased during the second year of histrelin treatment.
Peptide
Histrelin
Outcome
DecreasePeak LH in previously treated subjects
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · subcutaneous implantAs given in this study (human).
Measurements
Peak LH at 12 months (mean, SD 0.50)
0.74 mIU/mL
previously treated subjects
Peak LH at 24 months (mean, SD 0.35)
0.45 mIU/mL
previously treated subjects
Source sentences
Summary
and from 0.74 +/- 0.50 mIU/mL at 12 months to 0.45 +/- 0.35 mIU/mL at 24 months (P = .0081) in previously treated subjects.
2 context sentences(design, population, supporting numbers)
Summary · context
The study evaluates a second year of therapy in children with CPP who received a new implant after one year of treatment.
Summary · context
A prospective one-year study following an initial 12-month treatment period was conducted.
Report a problemFND-1995669902

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.